HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI

International Journal of Cancer

Volumn 76, Issue 5, 1998, Pages 749-756

  Rao, C N ^a   Cook, B ^a   Liu, Yueying ^a   Chilukuri, Krishna ^a   Stack, M Sharon ^a   Foster, Donald C ^b   Kisiel, W ^c   Woodley, David T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ZYMOGENETICS INC   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SERINE PROTEINASE INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROSARCOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION;

ANTINEOPLASTIC AGENTS; COLLAGEN; DRUG COMBINATIONS; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSARCOMA; GLYCOPROTEINS; HUMANS; LAMININ; NEOPLASM INVASIVENESS; PLASMIN; PREGNANCY PROTEINS; PROTEOGLYCANS; RECOMBINANT PROTEINS; SERINE PROTEINASE INHIBITORS; SKIN; TUMOR CELLS, CULTURED;

EID: 0031780347     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y     Document Type: Article

References (38)

1. ALBINI, A., IWAMOTO, H., KLEINMAN, H.K., MARTIN, G.R., AARONSON, S.A., KOZLOWSKI, J.M. and MCEWAN, R.N., A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res., 47, 3239-3245 (1987).
2. BIZIK, J., LIZINOVA, A., STEPHENS, R.W., GROFOVA, M. and VAHERI, A., Plasminogen activation by tPA on the surface of human melanoma cells in the presence of α2-macroglobulin secretion. Cell Regul., 1, 895-905 (1990).
3. BUTZOW, R., HUHTALA, M.L., BOHN, H., VIRTANEN, I. and SEPPALA, M., Purification and characterization of placental protein-5. Biochem. biophys. Res. Comm., 150, 483-490 (1988).
4. CAJOT, J.F., SCHLEUNING, W.D., MEDCALF, R.L., BAMAT, J., TESTUZ, L. and SORDAT, B., Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion. J. Cell Biol., 109, 915-925 (1989).
5. CROWLEY, C.W., COHEN, R.L., LUCAS, B.K., LIU, G., SHUMAN, M.A. and LEVINSON, A.D., Prevention of metastasis by inhibition of the urokinase receptor. Proc. nat. Acad. Sci. (Wash.), 90, 5021-5025 (1993).
6. DANØ, K., ANDREASEN, P.A., GRØNDAHL-JOHNSON, J., KRISTENSEN, P., NIELSEN, L.S. and SKRIVER, L., Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44, 139-239 (1985).
7. EITZMAN, D.T., KRAUSS, J.C., SHEN, T. and GINSBURG, D., Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood, 87, 4718-4722 (1996).
8. FAZIOLI, F. and BLASI, F., Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharm. Sci., 15, 25-29 (1994).
9. GOOLSBY, C.L., WILEY, J.E., STEINER, M., BARTHOLDI, M.F., SCOTT-CRAMM, L. and KRAEMER, P.M., Karyotype evolution in a simian virus 40-transformed tumorigenic human cell line. Cancer Genet. Cytogenet., 49, 231-248 (1991).
10. JONES, P.A. and DECLERCK, Y.A., Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells. Cancer Res., 40, 3222-3227 (1980).
11. KISIEL, W., SPRECHER, C.A. and FOSTER, C.A., Evidence that a second human tissue factor pathway inhibitor-2 (TFPI-2) and human placental protein-5 are equivalent (letter). Blood, 84, 4384-4385 (1994).
12. KNUDSEN, B.S., SILVERSTEIN, R.L., LEUNG, L.L.K., HARPEL, P.C. and NACHMAN, R.L., Binding of plasminogen to extracellular matrix. J. biol. Chem., 261, 10765-10771 (1985).
13. KOBAYASHI, H., GOTOH, J., HIRASHIMA, Y., FUJIE, M., SUGINO, D. and TERAO, T., Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J. biol. Chem., 270, 8361-8366 (1995).
14. KRAMER, M.D., REINARTZ, J., BRUNNER, G. and SCHIRRMACHER, V., Plasmin in pericellular proteolysis and cellular invasion. Invasion Metastasis, 14, 210-222 (1994).
15. KWAAN, H.C., The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev., 11, 291-311 (1992).
16. LINO, M., FOSTER, D.C. and KISIEL, W., Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler. Thromb. Vasc. Biol., 18, 40-46 (1998).
17. MIGNATTI, P. and RIFKIN, D.B., Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev., 73, 161-195 (1995).
18. MIMURO, J., SCHLEEF, R.R. and LOSKUTOFF, D.J., Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood, 70, 721-728 (1987).
19. MIN, Y.H., DOYLE, V.L., VITT, C.R., ZANDONELLA, C.L., STRATTON-THOMAS, J.R., SHUMAN, M.A. and ROSENBERG, M., Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngenic mice. Cancer Res., 56, 2428-2433 (1996).
20. MIYAGI, Y., YASUMITSU, H., KOSHIKAWA, N., MATSUDA, Y., ITOH, H., HORI, T.-A., AOKI, I., MISUGI, K. and MIYAZAKI, K., Cloning of the cDNA encoding mouse PP5/TFPI-2 and mapping of the gene to chromosome 6. DNA Cell Biol., 15, 975-954, (1996a).
21. MIYAGI, Y., YASUMITSU, H., MIYATA, S., KKAWA, N., HIRAHARA, F., AOKI, I., MISUGI, K. and MIYAZAKI, K., Assignment of the human PP5/TFPI-2 gene to 7Q 22 by FISH and PCR-based human mapping panel analysis. Genomics, 35, 267-268 (1996b).
22. MONTESANO, R., PEPPER, M.S., MOHLE-STEINLEIN, U., RISAU, W., WAGNER, E.F. and ORCI, L., Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing middle T oncogene. Cell, 32, 319-328 (1990).
23. NIP, J., RABBANI, S.A., SHIBATA, H.R. and BRODT, P., Coordinated expression of the vitronectin receptor and the urokinase type-plasminogen activator receptor in metastatic melanoma cells. J. clin. Invest., 95, 2096-2103 (1995).
24. OSSOWSKI, L., In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface bound urokinase. J. Cell Biol., 107, 2437-2445 (1988).
25. PETERSEN, L.C., SPRECHER, C.A., FOSTER, D.C., BLUMBERG, H., HAMAMOTO, T. and KISIEL, W., Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry, 35, 266-272 (1996).
26. PIERSCHBACHER, M.D. and RUOSLAHTI, E., Variants of the cell recognition site of fibronectin that retain attachment promoting activity. Proc. nat. Acad. Sci. (Wash.), 81, 5985-5988 (1984).
27. QUATTRONE, A., FABBI, G., ANICHINI, E., PUCCI, M., ZAMPERINI, A., CAPACCIOLI, S. and DEL ROSSO, M., Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res., 55, 90-95 (1995).
28. QUAX, P.H.A., VAN MUIJEN, G.N.P., WEENING-VERHOFF, E.J.D., LUND, L.R., DANØ, K., RUITER, D.J. and VERHEIJEN, J.H., Metastatic behavior of human melanoma cells in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor and urokinase-mediated degradation. J. Cell Biol., 115, 191-199 (1991).
29. RAO, C.N., GOMEZ, D.E., WOODLEY, D.T. and THORGEIRSSON, U.P., Partial characterization of novel serine protease inhibitors from human umbilical vein endothelial cells. Arch. Biochem. Biophys., 319, 55-62 (1995a).
30. RAO, C.N., LIU, V.Y., PEAVEY, C.L., and WOODLEY, D.T., Novel extracellular matrix-associated serine protease inhibitors from human skin cells. Arch. Biochem. Biophys., 317, 311-314 (1995b).
31. RAO, C.N., PEAVEY, C.L., LIU, Y.Y., LAPIERE, J.C. and WOODLEY, D.T., Partial characterization of matrix-associated serine protease inhibitors from humun skin cells. J. invest. Dermatol., 104, 379-383 (1995c).
32. RAO, C.N., PRASAD REDDY, LIU, Y.Y., O'TOOLE, E.A.O., REEDER, D.J., FOSTER, D.C., KISIEL, W. and WOODLEY, D.T., Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch. Biochem. Biophys., 335, 82-92 (1996).
33. REINARTZ, J., BATRLA, R., BOUKAMP, P., FUSENIG, N. and KRAMER, M.D., Binding and activation of plasminogen at the surface of human keratinocytes. Exp. Cell Res., 208, 197-208 (1993).
34. SABAPATHY, T.K., PEPPER, M.S., KIEFER, F., MOHLE-STEINLEIN, U., TACCHINI-COTTIER, F., FETKA, I., BREIER, G., RISAU, W., CARMELIET, P., MONTESANO, R. and WAGNER, E.F., Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system. J. Cell Biol., 137, 953-963 (1997).
35. SPRECHER, C.A., KISIEL, W., MATHEWES, S. and FOSTER, D.C., Molecular cloning, expression and partial characterization of a noxel human tissue factor pathway inhibitor. Proc. natl. Acad. Sci. (Wash.), 91, 3353-3357 (1994).
36. STAHL, A. and MUELLER, B.M., Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res., 54, 3066-3071 (1994).
37. STEPHENS, R.W., PÖLLANEN, J., TAPIOVAARA, H., LEUNG, K.C., SIM, P.S., SALONEN, E.M., ROØNNE, E., BEHRENDT, N., DANO, K., and VAHERI A., Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J. Cell Biol., 108, 1987-1995 (1989).
38. TOWBIN, H., STAEHELIN, T. and GORDON, J., Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to nitrocellulose sheets: procedures and some applications. Proc. nat. Acad. Sci. (Wash.), 76, 4350-4354 (1979).